UEG

Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Results; Achieves 2023 Financial Guidance

Retrieved on: 
Donnerstag, Februar 15, 2024
Managed Care, Biotechnology, Pharmaceutical, Health, Acquisition, Liver, Autoimmune disease, Income tax, Hepatology, FDA, Food, Endometriosis, PBC, Interest expense, Constipation, Annual general meeting, Short bowel syndrome, Safety, Society, GAAP, The Lancet, UEG, Pharmacokinetics, Food and Drug Administration, Primary biliary cholangitis, Interest, Patient, Disease, STARS, Phase, Interstitial cystitis, Trial of the century, Ageing, United European Gastroenterology, CIC, Research, SBS, Depreciation, Video game

Total revenues in the fourth quarter of 2023 were $117.6 million, compared to $107.2 million in the fourth quarter of 2022.

Key Points: 
  • Total revenues in the fourth quarter of 2023 were $117.6 million, compared to $107.2 million in the fourth quarter of 2022.
  • Operating expenses in the fourth quarter of 2023 were $80.0 million, compared to $38.8 million in the fourth quarter of 2022.
  • Adjusted EBITDA was $39.9 million in the fourth quarter of 2023, compared to $68.7 million in the fourth quarter of 2022.
  • Ironwood generated $35.8 million in cash from operations in the fourth quarter of 2023, compared to $79.2 million in cash from operations in the fourth quarter of 2022.

Ironwood Pharmaceuticals Reports Third Quarter 2023 Results

Retrieved on: 
Donnerstag, November 9, 2023
Research, FDA, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, Other Science, Science, Graft-versus-host disease, United European Gastroenterology, Short bowel syndrome, Constipation, Trial of the century, Income tax, Interstitial cystitis, Hepatology, Interest expense, EBITDA, Test Claimants in the Franked Investment Income Group Litigation v IRC, Liver, STARS, GAAP, Acquisition, SBS, Interest, PBC, Society, Pharmacokinetics, Phase, Clinical trial, Annual general meeting, Primary biliary cholangitis, Autoimmune disease, Depreciation, UEG, Safety, Total, CIC, Patient, Endometriosis, Pharmaceutical industry, Vaccine, Video game, Bookkeeping, Reinsurance, Bank, Ironwood, Nutrition

Total revenues in the third quarter of 2023 were $113.7 million, compared to $108.6 million in the third quarter of 2022.

Key Points: 
  • Total revenues in the third quarter of 2023 were $113.7 million, compared to $108.6 million in the third quarter of 2022.
  • Operating expenses in the third quarter of 2023 were $73.7 million, compared to $40.2 million in the third quarter of 2022.
  • Adjusted EBITDA was $49.1 million in the third quarter of 2023, compared to $68.8 million in the third quarter of 2022.
  • – Ironwood generated approximately $32.5 million in cash from operations in the third quarter of 2023, compared to $69.1 million in cash from operations in the third quarter of 2022.

Schrödinger Reports Third Quarter 2023 Financial Results

Retrieved on: 
Mittwoch, November 1, 2023
Software, Biotechnology, Pharmaceutical, Oncology, General Health, Health, Technology, Clinical Trials, United European Gastroenterology, PH, PRMT5, Trial of the century, Global health, IND, Acute myeloid leukemia, MALT1, Food, PKA, FEP, Myelodysplastic syndrome, Regulation of tobacco by the U.S. Food and Drug Administration, GAAP, Mantle cell lymphoma, Research, Bill, Ulcerative colitis, Bill & Melinda Gates Foundation, Pharmacokinetics, CDC7, Phases of clinical research, Webcast, ADMET, UEG, Safety, Overweight, Therapy, Investment, Table, Patient, Cryptocurrency, Pharmaceutical industry, Bank, EU

Schrödinger today updated its financial guidance for 2023.

Key Points: 
  • Schrödinger today updated its financial guidance for 2023.
  • The Phase 1 dose-escalation study in healthy volunteers is nearing completion, and the company expects to report data from the study in the fourth quarter of 2023.
  • Schrödinger will host a conference call to discuss its third quarter 2023 financial results on Wednesday, November 1, 2023, at 4:30 p.m.
  • Schrödinger will host its Pipeline Day in New York City on Thursday, December 14, 2023, beginning at 10:00 a.m.

Morphic Therapeutic to Host Webcast to Present EMERALD-1 Full Data Set

Retrieved on: 
Montag, Oktober 9, 2023
Ulcerative colitis, Webcast, Conditional sentence, UEG, Pharmaceutical industry

The positive topline results from EMERALD-1 were reported in April of this year and the full data set will be presented at the upcoming UEG Week 2023.

Key Points: 
  • The positive topline results from EMERALD-1 were reported in April of this year and the full data set will be presented at the upcoming UEG Week 2023.
  • The webcast and call will be held at 7:45 AM Eastern Time on October 12, 2023.
  • A live webcast of the call will be available via this link or on the Investors section of Morphic’s website, at www.morphictx.com.
  • To join the question-and-answer queue on the live conference call, please click here to register and receive a personalized dial in number.

EQS-News: Mainz Biomed to Showcase ColoAlert® at UEG Week 2023 in Copenhagen, Denmark

Retrieved on: 
Dienstag, Oktober 17, 2023
Partnership, Oncology, Thomas Jefferson National Accelerator Facility, United European Gastroenterology, Showcase, CRC, Cancer, Colorectal cancer, UEG, Gastroenterology

Mainz Biomed to Showcase ColoAlert® at UEG Week 2023 in Copenhagen, Denmark

Key Points: 
  • Mainz Biomed to Showcase ColoAlert® at UEG Week 2023 in Copenhagen, Denmark
    The issuer is solely responsible for the content of this announcement.
  • Mainz Biomed to Showcase ColoAlert® at UEG Week 2023 in Copenhagen, Denmark
    Mainz Biomed team members will be available throughout the event at the Company’s booth located in Hall C, Stand C3-92
    BERKELEY, US – MAINZ, Germany – October 11, 2023 — Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a leading molecular genetics diagnostic company focused on early cancer detection, announced today its participation in the upcoming UEG Week.
  • Recognized as a key gathering in the field, UEG Week addresses critical issues in gastroenterology, providing an ideal opportunity for Mainz Biomed to engage with international gastroenterologists, oncologists, and stakeholders interested in advancing the early detection of colorectal cancer (CRC).
  • Mainz Biomed team members will be available throughout the event showcasing ColoAlert® the Company’s flagship product, a highly effective and user-friendly at-home detection test for colorectal cancer (CRC).

Data Presented at UEG Week 2023 Further Support the Potential of Celltrion’s Investigational Subcutaneous Infliximab CT-P13 SC in the Treatment of Inflammatory Bowel Disease

Retrieved on: 
Montag, Oktober 16, 2023
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Incidence, European Commission, Health care, United European Gastroenterology, Northwestern Medicine, Feinberg School of Medicine, Mayo, CD, Aes, MD, BLA, IBD, Crohn's disease, Safety, Medicine, Ulcerative colitis, Patient, FDA, Biologics license application, Celltrion, CDAI, Maintenance, Infliximab, Inflammatory bowel disease, UEG, Infection, Pharmaceutical industry, Medical imaging, UC

The proportion of patients who experienced adverse events (AEs), serious AEs, infection in the SC infliximab and placebo groups were generally comparable.

Key Points: 
  • The proportion of patients who experienced adverse events (AEs), serious AEs, infection in the SC infliximab and placebo groups were generally comparable.
  • If approved by the FDA, CT-P13 SC would be the first subcutaneous formulation of infliximab.
  • Post-hoc analyses of the LIBERTY-CD and LIBERTY-UC studies were presented as posters at UEG Week 2023.
  • The first post-hoc analysis examined the possible use of SC infliximab treatment without immunosuppressants and the second evaluated dose escalation in patients with loss of treatment response.

Ironwood Pharmaceuticals Presents Positive Final Data from STARS Nutrition, a Phase II Study of Apraglutide in Short Bowel Syndrome with Intestinal Failure (SBS-IF) and Colon in Continuity (CIC) at United European Gastroenterology Week

Retrieved on: 
Montag, Oktober 16, 2023
Health, FDA, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Short bowel syndrome, Pharmacokinetics, United European Gastroenterology, Weaning, Risk, Trial of the century, Safety, Survival, Bronchoscopic lung volume reduction, Colon, SBS, Growth, PS, Gambat Liver Transplant Center, Ironwood Pharmaceuticals, Patient, UEG, Infection, Medication, CIC, Parenteral nutrition, STARS, Nutrition, Quality of life, Pharmaceutical industry, Birth control, Ironwood, Basel

Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a global GI-focused healthcare company, presented positive final data from the company’s Phase II STARS Nutrition program during United European Gastroenterology (UEG) Week.

Key Points: 
  • Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a global GI-focused healthcare company, presented positive final data from the company’s Phase II STARS Nutrition program during United European Gastroenterology (UEG) Week.
  • PS reduction was observed as early as week four and was maintained until the end of the study.
  • Seventy-eight percent (78%) of patients gained one or more days off PS with all patients achieving clinical response.
  • “We welcome these results and are continuing to progress the apraglutide development in the SBS-IF program with a sense of urgency.”

Palatin Presents Data at the United European Gastroenterology Week 2023 Conference On PL8177 Ulcerative Colitis Treatment

Retrieved on: 
Montag, Oktober 16, 2023
NYSE, Inflammation, Safety, United European Gastroenterology, Bremelanotide, Colitis, DSS, Inflammatory bowel disease, UEG, Melanocortin, Conference, Patient, Poster, Pharmaceutical industry, Rat, Palatine

The poster is currently available on the UEG 2023 Conference website.

Key Points: 
  • The poster is currently available on the UEG 2023 Conference website.
  • "This important mechanism of action data supports our active business development efforts for PL8177, including continued enrollment of patients in a Phase 2 ulcerative colitis study."
  • The poster presents data from a series of oral PL8177 dose-ranging studies in the DSS colon inflammation model and includes histological, genomic, and proteomic data.
  • PL8177 treatment showed clear evidence of resolving pathological inflammation by repolarizing colon macrophages from a pro-inflammatory to a pro-inflammation resolving state.

UEG Week 2023 : Babies with a low birthweight four times more likely to develop fatty liver disease in later life

Retrieved on: 
Sonntag, Oktober 15, 2023
Fatty liver disease, Ageing, UEG

COPENHAGEN, Denmark, Oct. 16, 2023 /PRNewswire/ -- A groundbreaking new study, presented today at UEG Week 2023, has discovered a significant connection between birthweight and the onset of nonalcoholic fatty liver disease, now known as metabolic dysfunction-associated steatotic liver disease (MASLD), in young people.

Key Points: 
  • COPENHAGEN, Denmark, Oct. 16, 2023 /PRNewswire/ -- A groundbreaking new study, presented today at UEG Week 2023, has discovered a significant connection between birthweight and the onset of nonalcoholic fatty liver disease, now known as metabolic dysfunction-associated steatotic liver disease (MASLD), in young people.
  • Notably, babies with a low birthweight were found to be four times more likely to develop MASLD in childhood, adolescence or young adulthood.
  • Individuals born with a low birthweight (
  • It is important that we develop proactive and effective strategies to identify at-risk individuals and help reduce the burden of this disease."

UEG Week 2023 : Babies with a low birthweight four times more likely to develop fatty liver disease in later life

Retrieved on: 
Sonntag, Oktober 15, 2023
Fatty liver disease, Ageing, UEG

COPENHAGEN, Denmark, Oct. 16, 2023 /PRNewswire/ -- A groundbreaking new study, presented today at UEG Week 2023, has discovered a significant connection between birthweight and the onset of nonalcoholic fatty liver disease, now known as metabolic dysfunction-associated steatotic liver disease (MASLD), in young people.

Key Points: 
  • COPENHAGEN, Denmark, Oct. 16, 2023 /PRNewswire/ -- A groundbreaking new study, presented today at UEG Week 2023, has discovered a significant connection between birthweight and the onset of nonalcoholic fatty liver disease, now known as metabolic dysfunction-associated steatotic liver disease (MASLD), in young people.
  • Notably, babies with a low birthweight were found to be four times more likely to develop MASLD in childhood, adolescence or young adulthood.
  • Individuals born with a low birthweight (
  • It is important that we develop proactive and effective strategies to identify at-risk individuals and help reduce the burden of this disease."